There are currently 824 clinical trials in Indianapolis, Indiana looking for participants to engage in research studies. Trials are conducted at various facilities, including Indiana University, Indiana University Melvin and Bren Simon Cancer Center, Riley Hospital for Children and Indiana University Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
STTEPP: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis
NCT05603702
Recruiting
The investigators propose to conduct a dose-escalation trial of an FDA-approved antiepileptic drug, lacosamide, added to opioid therapy in patients with chronic abdominal pain from chronic pancreatitis (CP). This pilot trial will test the feasibility of the study design and provide reassurance regarding the tolerability and safety of lacosamide used concomitantly with opioids in this patient population to reduce the condition known clinically as opioid-induced hyperalgesia (OIH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
Register for Updates
CYTALUX™for the Intraoperative Imaging of Prostate Cancer
NCT06434909
Recruiting
This study is being done to compare how much using Cytalux™ (pafolacianine) with NIR (Near InfraRed) fluorescent imaging improves the detection of malignant (growing in an uncontrolled way) tissue in adult subjects undergoing prostatectomy and lymph node dissection for biopsy confirmed prostate cancer. The U.S. Food and Drug Administration (FDA) has approved the targeted imaging agent pafolacianine (Cytalux) for use in ovarian cancer (2021) and lung cancer surgery (2022.)
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/27/2025
Locations: Indiana University Health Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Prostate Cancer
Register for Updates
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
NCT02932618
Recruiting
The main aim of the study is to check effectiveness, side effects, and tolerability of vonicog alfa (recombinant von Willebrand factor \[rVWF\]), with or without ADVATE, in the treatment and control of nonsurgical bleeding events in pediatric participants (less than (\<)18 years of age) with severe hereditary von Willebrand disease (VWD). The participants will be treated with vonicog alfa for 12-18 months. Their von Willebrand Disease will be treated by their doctor according to their doctor's... Read More
Gender:
ALL
Ages:
17 years and below
Trial Updated:
04/25/2025
Locations: Indiana Hemophilia and Thrombosis Center, Indianapolis, Indiana
Conditions: Von Willebrand Disease
Register for Updates
Citadel Embolization Device Study
NCT04057352
Recruiting
The purpose of this study is to gather safety and effectiveness data on Stryker Neurovascular's Next Generation Target Detachable Coil (hereafter referred to as the Citadel Embolization Device), when used with Target Detachable Coils, in the treatment of wide-neck intracranial aneurysms.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/24/2025
Locations: Indiana Methodist, Indianapolis, Indiana
Conditions: Unruptured Wide-neck Aneurysms
Register for Updates
Denosumab for Type 1 Diabetes
NCT06524960
Recruiting
Type 1 diabetes (T1D) arises from abnormal immune cell-mediated injury to beta cells that make insulin. The injured beta cells can then no longer make the needed amount of insulin to stay healthy. However, in the early stages of T1D, some beta cells are still alive and functioning. Treatment to protect the beta cells against injury at this time could slow the progress of disease. Denosumab is an approved treatment for osteoporosis (a disease that thins and weakens the bones), high blood calcium... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
04/24/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Type 1 Diabetes
Register for Updates
Master Protocol for Evaluating Multiple Infection Diagnostics for Ciprofloxacin-Resistant Neisseria Gonorrhoeae
NCT06815536
Recruiting
The goal of this study is to learn if a few investigational tests can correctly find the gene mutation (mutant allele gyrA 91F) that predicts ciprofloxacin resistance in clinical specimens that harbor Neisseria gonorrhoeae. The main question the study aims to answer: Can the investigational reflex test find the correct gene mutation (Neisseria gonorrhoeae gyrA 91F or gyrA 91S) as compared to the sequenced result? Specimens that are collected for routine clinical care and harbor Neisseria gonor... Read More
Gender:
ALL
Ages:
All
Trial Updated:
04/24/2025
Locations: Indiana University School of Medicine, Indianapolis, Indiana
Conditions: Neisseria Gonorrheae Infection
Register for Updates
Daily Hand-Held Vibration Therapy
NCT04207437
Recruiting
The purpose of this pilot study is to determine the safety and feasibility of a daily 3-minute hand-held vibration therapy intervention to reduce the severity of CIPN in the hands. The investigators hypothesize that daily vibration therapy can reduce the severity of patient's CIPN in their hands and improve CIPN-related quality of life. The hope is that results from this study will provide early data on the feasibility, efficacy, and most importantly, safety, of daily 3-minute hand-held vibratio... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/23/2025
Locations: Indiana University Melvin & Bren Simon Cancer Center, Indianapolis, Indiana +1 locations
Conditions: Neuropathy, Cancer, Chemotherapeutic Drug - Induced Nephropathy, Chemotherapeutic Toxicity
Register for Updates
A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion
NCT06360354
Recruiting
The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted gastrointestinal, biliary tract, or pancreatic cancers. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/23/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Advanced Gastrointestinal, Biliary Tract, and Pancreatic Cancers
Register for Updates
Circulating Tumor Cells (CTC) in Lung Cancer
NCT02630615
Recruiting
The primary objective of this study is to establish circulating tumor cell (CTC) derived xenografts and assess the activity of novel DNA repair inhibitors as a function of DNA repair mutations detected in CTC samples (personalize DNA repair therapy).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: Indiana University Health Hospital, Indianapolis, Indiana +2 locations
Conditions: Lung Neoplasms
Register for Updates
Conditioning SCID Infants Diagnosed Early
NCT03619551
Recruiting
The investigators want to study if lower doses of chemotherapy will help babies with SCID to achieve good immunity with less short and long-term risks of complications after transplantation. This trial identifies babies with types of immune deficiencies that are most likely to succeed with this approach and offers them transplant early in life before they get severe infections or later if their infections are under control. It includes only patients receiving unrelated or mismatched related dono... Read More
Gender:
ALL
Ages:
Between 0 years and 2 years
Trial Updated:
04/22/2025
Locations: Indiana University Hospital/Riley Hospital for Children, Indianapolis, Indiana
Conditions: SCID
Register for Updates
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
NCT05733520
Recruiting
This study is a randomized, controlled trial (RCT) to evaluate the effect of Brain CareNotes (a mobile health application) on the burden experienced by unpaid caregivers of patients with dementia and on the behavioral and psychological symptoms of dementia (BPSD) displayed by care recipients. Over 39 months, the trial will enroll 160 caregivers of community-dwelling patients diagnosed with Alzheimer's disease or a related dementia (ADRD). Caregivers will be randomized to use the Brain CareNotes... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/22/2025
Locations: IU Health, Indianapolis, Indiana +1 locations
Conditions: Caregiver Burden, Alzheimer Disease
Register for Updates
Establishing Baseline Sysmex UF-5000 Flow Cytometer Results in Healthy Men
NCT06951009
Recruiting
Acute urethritis (inflammation of the male urethra) affects millions of men in the United States each year. Effective management of STIs is complicated by asymptomatic infections, as men often delay seeking care until symptoms become severe. Yet, even men without symptoms can show measurable evidence of urethritis. Therefore, a cheap, simple, and non-invasive point-of-care (POC) test, providing results within 30 minutes, could significantly enhance STI management by facilitating early diagnosis... Read More
Gender:
MALE
Ages:
Between 18 years and 50 years
Trial Updated:
04/22/2025
Locations: Indiana University, Indianapolis, Indiana
Conditions: Urethritis, Healthy Men Age 18-50 With no Urethral Symptoms
Register for Updates